by Fecal Calprotectin Test Market is an important tool for diagnosing and monitoring inflammatory bowel diseases such as Crohn’s disease and ulcerative colitis. It is a protein found in the white blood cells that travel to the intestines when there is an inflammation. Elevated levels of fecal calprotectin indicate the presence of inflammation in the intestines. The test is non-invasive and provides quicker results than other diagnostic tests such as endoscopy or colonoscopy. It helps in the prompt initiation of appropriate treatment and prevents unnecessary invasive procedures.
The Global Fecal Calprotectin test Market is estimated to be valued at US$ 161.98 Mn in 2024 and is expected to exhibit a CAGR of 3.9% over the forecast period 2024 to 2030.
Key Takeaways
Key players operating in the Fecal Calprotectin test market are John Deere, Vermeer Corporation, Kuhn Group, AGCO Corporation, Krone North America, New Holland Agriculture, Claas Group, Kubota Corporation, Fella Maschinenbau GmbH, Sitrex S.p.A., Deutz-Fahr, Enorossi, Tonutti, Galfre, Pottinger Agricultural Machinery.
Key opportunities in the market include development of rapid point-of-care tests which can provide quick results without the need for lab processing. Home-based sample collection tests are also gaining traction as they enable testing from the convenience of home.
The market is witnessing high growth in developing regions of Asia Pacific and Latin America due to rising awareness and increasing incidences of digestive diseases. Key players are focusing on these emerging economies through partnerships with regional diagnostic service providers.
Market drivers
The key driver for the growth of Fecal Calprotectin Test Market Growth is the increasing occurrence of inflammatory bowel diseases across the globe. Other drivers include rising demand for early and accurate diagnosis of digestive diseases, growing geriatric population susceptible to digestive disorders, and increasing adoption of Calprotectin tests for monitoring of post-operative recurrence of Crohn’s disease and ulcerative colitis.
PEST Analysis
Political: Regulations related to IVD (in vitro diagnostics) devices and diagnostics testing may impact the market. However, rising awareness about IBD (inflammatory bowel disease) screening is encouraging adoption.
Economic: Rising healthcare expenditures especially in developing regions is creating demand for cost-effective IBD and colon cancer screening tests. Insurance coverage for such tests is expected to drive the market.
Social: Increasing incidence of IBD primarily due to changing lifestyle and diet is a key driver. Growing awareness about early screening and diagnosis among patients is supporting the market growth.
Technological: Automation and development of more convenient sample collection techniques are enhancing testing access. Integrating calprotectin detection with other tests is advancing diagnostics.
The geographical regions where the fecal calprotectin test market in terms of value is highly concentrated include North America and Europe. These developed markets have established healthcare systems and reimbursement structure conducive to diagnostic tests adoption. Also, increasing IBD prevalence due to lifestyle changes has spurred market growth in these regions.
Asia Pacific is poised to be the fastest growing regional market for fecal calprotectin tests during the forecast period. This is attributed to growing healthcare expenditures, developing healthcare infrastructure, rising discretionary spending on health, and increasing disease awareness in developing countries such as India and China. Improving access to diagnosis and screening services presents considerable opportunities for market players in Asia Pacific in the coming years.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
